Meghan Fitzgerald and Leslie Norwalk Appointed to QUANTA Dialysis Technologies BOD

Meghan Fitzgerald and Leslie Norwalk, have been appointed to the Company’s Board of Directors, effective immediately. These highly accomplished healthcare experts will advise QUANTA as it works to improve patient access to dialysis care, care pathways and cost efficiencies.

“We are honored to welcome Meghan and Leslie, two highly respected industry veterans, to QUANTA’s Board,” said Johan de Ruiter, chairman of QUANTA Dialysis Technologies. “The pandemic has emphasized how critical it is for patients and clinicians to have access to flexible, effective dialysis care. The expertise and proven track record Meghan and Leslie bring to QUANTA will be greatly beneficial to our Board as we continue working to bring SC+ directly to every patient in every setting.”

Meghan Fitzgerald is a global healthcare strategist, investor, academic and author. A highly-regarded expert, she has worked in every domain of healthcare—from front line patient care through the Fortune 500—while serving as an adjunct professor at Columbia University. Currently, Ms. Fitzgerald is a private equity investor where she serves as an advisor to several firms, including Goldman Sachs and Wellspring Capital. Prior, Ms. Fitzgerald was the chief executive officer and managing partner at Letter One’s inaugural health vehicle, where she allocated approximately $4 billion in three years within pharmaceutical services and animal health. Ms. Fitzgerald has spent nearly twenty years as an operator and strategist, working for many prominent healthcare firms, including Merck, Pfizer and Medco. She was also the executive vice president of strategy, mergers and acquisitions and health policy at Cardinal Health and a member of the executive committee. In addition to her board appointment at QUANTA, Ms. Fitzgerald is a member of the board of directors at Tenet Healthcare.

Leslie Norwalk is strategic counsel to Epstein Becker Green, P.C., EBG Advisors and National Health Advisors. She serves as an advisor to several private equity firms and, in addition to QUANTA, sits on the Boards of Directors of Neurocrine Biosciences, Arvinas, NuVasive, ModivCare, Magellan Health, and several privately held health care companies. In her prior role with the Bush Administration, Ms. Norwalk was acting administrator for the Centers for Medicare & Medicaid Services (CMS), where she managed the day-to-day operations of CMS, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. In addition, Ms. Norwalk was the agency’s deputy administrator, responsible for the implementation of the hundreds of changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit.

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.